Spectrum Pharmaceuticals and Onxeo Announce Complete Response in 67% of Patients with Peripheral T-Cell Lymphoma in Combination of Belinostat and Standard CHOP
December 06, 2015 at 19:16 PM EST
Spectrum Pharmaceuticals (Nasdaq: SPPI) and Onxeo S.A. (OTC: OXNXF) today jointly announced the results from their Phase 1 ...